Last reviewed · How we verify
NCT05813587
To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19
Phase 3 trial testing Meplazumab for injection in Post-COVID-19 in 121 participants. Completed in 26 October 2023.
14 September 2023
Quick facts
| Lead sponsor | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 121 |
| Start date | 23 March 2023 |
| Primary completion | 14 September 2023 |
| Estimated completion | 26 October 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Meplazumab for injection — full drug profile →
- Normal saline
Conditions studied
- Post-COVID-19 — all drugs for Post-COVID-19 →
Sponsor
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd — full company profile →
Who can join
Adults 18 to 84, any sex, with Post-COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial was a randomized, double-blind, placebo-controlled, loading phase III clinical study.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Fighting Post-COVID and ME/CFS - development of curative therapies.
Scheibenbogen C, Bellmann-Strobl JT, Heindrich C, Wittke K, et al · · 2023 · cited 32× · PMID 37396922 · DOI 10.3389/fmed.2023.1194754 -
CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target.
Yang XM, Bian H, Chen ZN. · · 2026 · cited 1× · PMID 41454696 · DOI 10.1002/advs.202518884
Verify or expand the search:
- PubMed search for NCT05813587
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Meplazumab for injection
Trials testing the same drug.
- NCT05679479 — Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19 · Phase 3 · completed
Other Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd trials
Trials by the same sponsor.
- NCT05679479 — Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19 · Phase 3 · completed
- NCT05679492 — Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19 · Phase 3 · withdrawn
- NCT05113784 — the Safety and Efficacy of Meplazumab in Patients With COVID-19 · Phase 2, PHASE3 · completed
- NCT04586153 — Study to Assess the Effect of Meplazumab on COVID-19 · Phase 2, PHASE3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05813587 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
- Last refreshed: 28 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05813587.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing